Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nutrient transporters are a diverse group of membrane proteins, predominantly belonging to the Solute Carrier (SLC) superfamily, that facilitate the uptake of essential metabolic substrates such as glucose, amino acids, and monocarboxylates (Lin et al., 2015). In solid tumors, these transporters are frequently overexpressed to support the high metabolic demands of rapid cell proliferation and to maintain homeostasis within the acidic, nutrient-depleted tumor microenvironment (Scalise et al., 2018). Key examples include GLUT1 (SLC2A1) for glucose uptake, LAT1 (SLC7A5) and ASCT2 (SLC1A5) for amino acid transport, and MCT1/4 (SLC16A1/3) for lactate export (Barron et al., 2016; Payen et al., 2020). Pharmacological inhibition of these transporters aims to starve cancer cells by disrupting their energy supply and biosynthetic pathways, often leading to growth arrest or cell death (Scalise et al., 2018). These targets are particularly relevant in the context of the Warburg effect, where tumors rely heavily on glycolytic flux and amino acid metabolism (Lin et al., 2015). However, the therapeutic window is often limited by the expression of these transporters in healthy tissues, such as the blood-brain barrier, erythrocytes, and activated immune cells, which can lead to significant systemic toxicities (Lin et al., 2015). Current drug development efforts focus on highly selective small molecules like JPH203 and AZD3965 to minimize off-target effects (Payen et al., 2020). Monitoring efficacy often involves functional imaging techniques like FDG-PET, which tracks the activity of these transporters in vivo (Barron et al., 2016).
Inhibition of substrate transport (e.g., glucose, amino acids, or monocarboxylates) across the plasma membrane, leading to intracellular nutrient depletion, disruption of ATP production, and induction of metabolic stress or apoptosis (Lin et al., 2015; Payen et al., 2020).
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family transporters (SLC).